Jade Biosciences appoints Mark Eisner, former Vir CMO, to Board of Directors

Jade Biosciences, Inc.

Mark Eisner appointed as Class I director effective June 25, 2026; joins Nominating and Corporate Governance Committee.
Eisner most recently EVP & CMO at Vir Biotechnology; previously CMO at Sonoma Biotherapeutics and FibroGen, and 11 years at Genentech/Roche.
Received option for 47,675 shares vesting over 3 years; eligible for annual cash retainer under non-employee director program.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Eisner

Class I director

JBIO · Jade Biosciences, Inc.

Effective: 2026-06-25
Filed: June 26, 2026, 7:15 AM ET

On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Eisner was appointed as Class I director at Jade Biosciences, Inc..

Action: appointed
Role: Class I director

Exact text from the filing

On June 25, 2026, the Board of Directors (the “Board”) of Jade Biosciences, Inc. (the “Company”) appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.

View on SEC.gov

Jade Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-283906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.